BUYINS.NET Issues
Amarantus Bioscience
(AMBS)
SqueezeTrigger Report
- Approximately
113.8 Million
Total Shares Shorted
Since July
2015
- Short Squeeze Expected When
Stock Exceeds
$0.166
SqueezeTrigger
San
Francisco, CA. -- March 7, 2018 -- InvestorsHub newsWire
-- BUYINS.NET --
Amarantus Bioscience Holdings, Inc. (USOTC:AMBS)
(the "Company" or AMBS), a US-based biotechnology
holding company with wholly-owned subsidiaries developing
first-in-class orphan neurologic, regenerative medicine and
ophthalmic therapies, today announced that 7Mar.
SAN
FRANCISCO, http://www.buyins.net,
a leading provider of Regulation SHO compliance monitoring, short
sale trading statistics and market integrity
surveillance, has initiated
coverage on Amarantus
Bioscience (USOTC:
AMBS)
after releasing the latest short sale data through
March
6,
2018. The
total
aggregate number of shares
shorted since July
2015 is
approximately 113.8
million
shares.
Approximately
31.64%
of daily
trading volume is short selling. The SqueezeTrigger
price for all AMBS
shares
shorted is $0.166.
A short
squeeze is expected to
begin
when
shares
of AMBS
exceed
this level
Click here to
view Report: http://www.buyins.com/reports/ambs3-7-18.pdf
Click here for
SqueezeTrigger: http://www.buyins.com/images2/ambsstr3-7-18.jpg
Click here for
Friction Factor: http://www.buyins.com/images2/ambsff3-7-18.jpg
Click here for
detailed explanation: http://www.buyins.com/brochure.pdf
Friction Factor
calculates if a fair market is being made in the
shares of AMBS.
51% of the
previous 35 trading days have
been positive or
bullish-biased and 49% have been negative
or bearish-biased.
Regulation SHO
requires bona-fide market-making activities to include making
purchases and sales in roughly comparable amounts. The Commission
has stated that bona-fide market-making DOES NOT include activity
that is related to speculative selling strategies
for investment
purposes of the broker-dealer and is disproportionate to the usual
market making patterns or practices of the broker-dealer in that
security. Likewise, where a market-maker posts continually at or
near the best offer, but does not also post at or near the best
bid, the market-maker's activities would not generally qualify as
bona-fide market-making. Moreover, a market-maker that continually
executes short sales away from its posted quotes would generally
not be considered to be engaging in bona-fide
market-making.
BUYINS.NET
monitors AMBS
market-makers daily
for compliance with Fair Market-Making Requirements.
About BUYINS.NET
BUYINS.NET,
http://www.buyins.net,
comparable
valuations. , hedge fund trading
strategies andmonitors trading in
all US stocks in real time and maintains massive databases of short
sale and naked short sale time and sales data, short squeeze
SqueezeTrigger prices, market-maker price movements, shareholder
data, statistical data on earnings, sector correlation,
seasonality
About
Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience
Holdings (AMBS) is a biotechnology company developing treatments
and diagnostics for diseases in the areas of neurology,
regenerative medicine and orphan diseases through its subsidiaries.
AMBS' wholly-owned subsidiary Elto
Pharma, Inc. has development
rights to eltoprazine, a Phase 2b-ready small molecule indicated
for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's
aggression and adult attention deficit hyperactivity disorder,
commonly known as ADHD. AMBS acquired the rights to the Engineered
Skin Substitute program (ESS), a regenerative medicine-based
approach for treating severe burns with full-thickness autologous
skin grown in tissue culture that is being pursued by AMBS'
wholly-owned subsidiary Cutanogen
Corporation. AMBS' wholly-owned
subsidiary MANF Therapeutics, Inc. owns key intellectual property
rights and licenses from a number of prominent universities related
to the development of the therapeutic protein known as
mesencephalic astrocyte-derived neurotrophic factor
("MANF"). MANF
Therapeutics, Inc. is
developing MANF-based products as treatments for brain and
ophthalmic disorders. MANF was discovered by the Company's Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong
discovered MANF from AMBS' proprietary discovery engine PhenoGuard.
AMBS also owns approximately 79.25 million shares of Avant
Diagnostics, Inc. via the sale of its wholly-owned subsidiary
Amarantus Diagnostics, Inc. that occurred in May 2016.
For
further information please visit www.Amarantus.com, or connect with
AMBS on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements,
other than purely historical information, including estimates,
projections, statements relating to our business plans, objectives,
and expected operating results, and the assumptions upon which
those statements are based, are forward-looking statements. These
forward-looking statements generally are identified by the words
"believes," "project," "expects," "anticipates," "estimates,"
"intends," "strategy," "plan," "may," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions.
Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties which may
cause actual results to differ materially from the forward-looking
statements. Our ability to predict results or the actual effect of
future plans or strategies is inherently uncertain. Factors which
could have a material adverse effect on our operations and future
prospects on a consolidated basis include, but are not limited to:
changes in economic conditions, legislative/regulatory changes,
availability of capital, interest rates and competition. These
risks and uncertainties should also be considered in evaluating
forward-looking statements and undue reliance should not be placed
on such statements.
DISCLAIMER:
BUYINS.NET is
not a registered
investment adviser and nothing
contained in any materials should be construed as a
recommendation to buy or sell any
securities. AMBS
has
paid
$1,500
per
month for
three
months
of data
provided
in
this
and
subsequent reports.
AMBS
has not
approved the statements made in this release. Please read our
report and visit our web site, http://www.buyins.net, for complete risks
and disclosures.
Contact:
BUYINS.NET
Thomas
Ronk
800-715-9999
tomronk@gmail.com
http://www.buyins.net
Amarantus
Investor and Media Contact:
Ascendant
Partners, LLC
Richard
Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus
Bioscience Holdings, Inc.